CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”) ...
Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the ...
LENSAR, Inc. (Nasdaq: LNSR) ('LENSAR” or the 'Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the ...
Narrow-moat Alcon discussed current projects and initiatives, pipeline progression, and long-term financial goals in its 2025 Capital Markets Day. After digesting the performance of each business unit ...
Please provide your email address to receive an email when new articles are posted on . Rumors swirled around the exhibit floor and coursed through gatherings of dry eye disease docs who attended the ...
Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the ...
Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results